Primer on immuno-oncology and immune response

Clinical Journal of Oncology Nursing

Volumn 18, Issue 3, 2014, Pages

  Kannan, Rajni ^a   Madden, Kathleen ^a   Andrews, Stephanie ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Immune responses; Immuno oncology; Immunotherapy; Patient management

Indexed keywords

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84901589433     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/14.CJON.311-317     Document Type: Article

References (54)

1. Abbas, A.K., & Lichtman, A.H. (2006). Introduction to the immune system. The nomenclature, general properties and components of the immune system. In A.K. Abbas, & A.H. Lichtman (Eds.), Basic immunology: Functions and disorders of the immune system (2nd edition, pp. 1-20). Philadelphia, PA: Saunders.
2. Anassi, E., & Ndefo, U.A. (2011). Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharmacy and Therapeutics, 36, 197-202.
3. Bhardwaj, N. (2007). Harnessing the immune system to treat cancer. Journal of Clinical Investigation, 117, 1130-1136.
4. Boasberg, P., Hamid, O., & O'Day, S. (2010). Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade. Seminars in Oncology, 37, 440-449.
5. Bristol-Myers Squibb. (2011). Yervoy™ (ipilimumab) [US package insert]. Princeton, NJ: Author.
6. Bristol-Myers Squibb. (2012). Yervoy (ipilimumab): Serious and fatal immune-mediated adverse reactions. Retrieved from http://www.yervoy.com/hcp/rems.aspx
7. Buzaid, A.C., & Atkins, M. (2001). Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clinical Cancer Research, 7, 2611-2619.
8. Coley, W.B. (1891). Contribution to the knowledge of sarcoma. Annals of Surgery, 14(3), 199-220.
9. Demaria, S., Bhardwaj, N., McBride, W.H., & Formenti, S.C. (2005). Combining radiotherapy and immunotherapy: A revived partnership. International Journal of Radiation Oncology Biology Physics, 63, 655-666.
10. Dendreon. (2010). Provenge® (sipuleucel-T) [package insert]. Seattle, WA: Author.
11. Di Lorenzo, G., Ferro, M., & Buonerba, C. (2012). Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. British Journal of Urology International, 110, E99-E104.
12. Dougan, M., & Dranoff, G. (2009). Immune therapy for cancer. Annual Review of Immunology, 27, 83-117.
13. Drake, C.G., & Antonarakis, E.S. (2012). Current status of immunological approaches for the treatment of prostate cancer. Current Opinion in Urology, 22, 197-202.
14. Dummer, R., Maio, M., Hamid, O., O'Day, S.J., Richards, J., Wolchok, J.D.,. Weber, J.S. (2010, September). Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. Poster session presented at Perspectives in Melanoma XIV, Amsterdam, Netherlands.
15. DuPage, M., Mazumdar, C., Schmid, L.M., Cheung, A.F., & Jacks, T. (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482, 405-409. doi:10.1038/nature10803
16. Flaherty, K.T. (2011). Next generation therapies change the landscape in melanoma. F1000 Medicine Reports, 3, 8.
17. Hanahan, D., & Weinberg, R.A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646-674. doi:10.1016/j.cell.2011.02.013
18. Harmankaya, K., Erasim, C., Koelblinger, C., Ibrahim, R., Hoos, A., Pehamberger, H., & Binder, M. (2011). Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Medical Oncology, 28, 1140-1144.
19. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B.,. Urba, W.J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711-723. doi:10.1056/NEJMoa1003466
20. Hoos, A., Eggermont, A.M., Janetzki, S., Hodi, F.S., Ibrahim, R., Anderson, A.,. Wolchok, J. (2010). Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute, 102, 1388-1397. doi:10.1093/jnci/djq310
21. Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V.,. Humphrey, R. (2010). Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Seminars in Oncology, 37, 533-546. doi:10.1053/j.seminoncol.2010.09.015
22. Ibrahim, R., Berman, D., de Pril, V., Humphrey, R.W., Chen, T., Messina, M.,. Hoos, A. (2011, June). Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Poster session presented at the American Society of Clinical Oncology 2011 Annual Meeting, Chicago, IL.
23. Imai, K., & Takaoka, A. (2006). Comparing antibody and small-molecule therapies for cancer. Nature Reviews. Cancer, 6, 714-727.
24. Johansson, A., Hamzah, J., Payne, C.J., & Ganss, R. (2012). Tumor-targeted TNF stabilizes tumor vessels and enhances active immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 109, 7841-7846. doi:10.1073/pnas.1118296109
25. Kantoff, P.W. (2010). Updated results of the IMPACT trial of sipuleucel-T for metastatic, castration-resistant prostate cancer. Retrieved from file:///C:/Users/jenderle/Downloads/ASCO%20GU%20SipT%20Final%20[Compatibility%20Mode]. pdf
26. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F.,. Schellhammer, P.F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363, 411-422. doi:10.1056/NEJMoa1001294
27. Kirkwood, J.M., Butterfield, L.H., Tarhini, A.A., Zarour, H., Kalinski, P., & Ferrone, S. (2012). Immunotherapy of cancer in 2012. CA: A Cancer Journal for Clinicians, 62, 309-335. doi:10.3322/caac.20132
28. Kirkwood, J.M., Tarhini, A.A., Panelli, M.C., Moschos, S.J., Zarour, H.M., Butterfield, L.H., & Gogas, H.J. (2008). Next generation of immunotherapy for melanoma. Journal of Clinical Oncology, 26, 3445-3455. doi:10.1200/JCO.2007.14.6423
29. Lemech, C., & Arkenau, H.T. (2012). Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clinical Medicine Insights: Oncology, 6, 53-66.
30. Lynch, T.J., Bondarenko, I.N., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R.T.,. Reck, M. (2010, June). Phase II trial of ipilimumab and paclitaxel/carboplatin in first-line stage IIIb/IV non-small cell lung cancer. Poster session presented at the American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL.
31. Medzhitov, R., Shevach, E.M., Trinchieri, G., Mellor, A.L., Munn, D.H., Gordon, S.,. O'Garra, A. (2011). Highlights of 10 years of immunology in Nature Reviews Immunology. Nature Reviews. Immunology, 11, 693-702. doi:10.1038/nri3063
32. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., & Chen, L. (2007). Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews. Cancer, 7, 95-106.
33. Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480, 480-489. doi:10.1038/nature10673
34. Nagorsen, D., Scheibenbogen, C., Marincola, F.M., Letsch, A., & Keilholz, U. (2003). Natural T cell immunity against cancer. Clinical Cancer Research, 9, 4296-4303.
35. Paller, C.J., & Antonarakis, E.S. (2012). Sipuleucel-T for the treatment of metastatic prostate cancer: Promise and challenges. Human Vaccine Immunotherapy, 8, 4509-519. doi:10.4161/hv.18860
36. Pandolfi, F., Cianci, R., Pagliari, D., Casciano, F., Bagalà, C., Astone, A.,. Barone, C. (2011). The immune response to tumors as a tool toward immunotherapy. Clinical and Developmental Immunology, 2011, 894704. doi:10.1155/2011/894704
37. Pazdur, R. (2013). FDA approval for ipilimumab. Retrieved from http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab
38. Peggs, K.S., Segal, N.H., & Allison, J.P. (2007). Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative. Cancer Cell, 12, 192-199.
39. Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P.,. Parmiani, G. (2002). Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunology Review, 188, 97-113.
40. Salama, A.K., & Hodi, F.S. (2011). Cytotoxic T-lymphocyte-associated antigen-4. Clinical Cancer Research, 17, 4622-4628. doi:10.1158/1078-0432.CCR-10-2232
41. Schmidt, C. (2012). Future of immunotherapy drug combinations and biomarkers. Journal of the National Cancer Institute, 104, 434-439. doi:10.1093/jnci/djs186
42. Sznol, M. (2012). Advances in the treatment of metastatic melanoma: New immunomodulatory agents. Seminars in Oncology, 39, 192-203. doi:10.1053/j.seminoncol.2012.01.007
43. Thara, E., Dorff, T.B., Averia-Suboc, M., Luther, M., Reed, M.E., Pinski, J.K., & Quinn, D.I. (2012). Immune response to Sipuleucel-T in prostate cancer. Cancers, 4, 420-441.
44. Thomas, J.A., & Badini, M. (2011). The role of innate immunity in spontaneous regression of cancer. Indian Journal of Cancer, 48, 246-251. doi:10.4103/0019-509X.82887
45. Thumar, J.R., & Kluger, H.M. (2011). Ipilimumab: A promising immunotherapy for melanoma. Oncology, 24, 1280-1288.
46. Tucker, Z.C., Laguna, B.A., Moon, E., & Singhal, S. (2012). Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 38, 650-661. doi:10.1016/j.ctrv.2011.11.008
47. Tuma, R.S. (2011). Immunotherapies in clinical trials: Do they demand different evaluation tools? Journal of the National Cancer Institute, 103, 780-781. doi:10.1093/jnci/djr184
48. Verschraegen, C. (2012). The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Management and Resources, 4, 1-8.
49. Vesely, M.D., Kershaw, M.H., Schreiber, R.D., & Smyth, M.J. (2011). Natural innate and adaptive immunity to cancer. Annual Review of Immunology, 29, 235-271.
50. Weber, J. (2010). Immune checkpoint proteins: a new therapeutic paradigm for cancer-Preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology, 37, 430-439.
51. Weber, J.S., Kähler, K.C., & Hauschild, A. (2012). Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 30, 2691-2697.
52. Witten, C. (2013). FDA approval for sipuleucel-T. Retrieved from http://www.cancer.gov/cancertopics/druginfo/fda-sipuleucel-T
53. Wolchok, J., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C.,. Hodi, F.S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15, 7412-7420.
54. Yu, P., Steel, J.C., Zhang, M., Morris, J.C., & Waldmann, T.A. (2010). Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clinical Cancer Research, 16, 6019-6028.